Congratulations to Vince Umbers, who completed a full 42.2km marathon on Saturday!
Vince ran this insane distance in honour of his dear friend, and CRBF Patient Advocate, Jack Gibson who was part of Vince’s support crew on the day.
On top of the rigorous training regime, Vince has been working overtime raising money, and has topped over $5000, all of which is heading straight to sarcoma research!
From all at CRBF, we would like to pass on our heartfelt thanks to Vince, for the hours of training and hard work that went into this event, to each of his outstanding support team on the day, and to the profound generosity of Vince’s supporters, for their donations.
All monies raised from Vince’s runs will go directly to the IL-23 sarcoma specific sub-study, at the Garvan Institute of Medical Research which is scheduled to commence early in 2021.
Monday 9 November, marked the launch of the National Oncology Alliance (NOA) Vision 20-30, with a three hour conference hosting major stakeholders, including hosting leading Australian oncologists and researchers, together with presentations from cancer patients and families.
It was three hours that provided hope for the future for those living with a cancer diagnosis, with a particular emphasis on those living with a rare cancer diagnosis. Vision 20-30 will place the magnifying glass on the current systems, and how they fit within the global context, with particular alignment to cell therapies, genomics and personalised therapeutics.
With support from the Minderoo Foundation, the Federal Government, and Rare Cancers Australia, Vision 20-30 will form the basis for advancing cancer in Australia.
A team of scientists led by Western Australian based scientist Dr. Emel Rothzerg – School of Biomedical Sciences at the University of The University of Western Australia, in Perth (Australia) and the Perron Institute for Neurological and Translational Science in Nedlands (Australia), reports an association between osteosarcoma and abnormal alternative splicing of the leptin receptor overlapping transcript (LEPROT).
Over 950 children and adolescents will be diagnosed with cancer each year in Australia.
One in five of these childhood cancers will be a sarcoma.
Each week, three children adolescents will die from cnacer.
Tow in five sarcoma patients will die from their disease. This increases if the cancer has spread upon diagnosis.
Childhood cancer survivors have a much higher risk of developing other malignancies later in life.
One in five sarcoma survivors will go on to develop a subsequent cancer or another sarcoma within ten years.
This month we shine the spotlight on the outstanding work of all cancer researchers, clinicians, dedicated nursing staff, treating hospitals and not for profits, whose focus is finding a cure through innovative clinical studies, improved standards of treatment and care, and funding research for childhood cancer.
It is also a time when we remember those children undergoing treatment, those yet to be diagnosed, and those who have tragically lost their lives to cancer in this country.
Sarcoma affects all ages, however it hits our young disproportionately hard.
As a dedicated sarcoma organisation, we wish to specifically highlight the outstanding work of Dr Emmy Fleuren, Senior Scientist, Zero Childhood Cancer Personalised Medicine Programme, Children’s Cancer Institute, whose research surrounding sarcoma specific high level tumour analysis stands to revolutionise the way we approach treatment for sarcoma in the future. Dr Fleuren joins her esteemed colleagues at the CCIA working tirelessly to advance a cure for all childhood cancers.
To hear more about Dr Fleuren’s remarkable Phosphoproteomics programme in our recent Let’s Talk About Sarcoma podcast series, click the link below.
We extend our heartfelt gratitude to all contributors working toward a cure for all childhood cancers.